Available Technologies
# of Displayed Technologies: 9 / 9
Applied Category Filter (Click To Remove): Antibodies
A new modular format for bispecific antibody fragments
TS-068425 — Functionalization of scFvs with cyclic peptide linkers
The Need
The high specificity of antibodies has been utilized to develop numerous technologies, tools and therapeutics, like ADCs and radiopharmaceuticals. Engineered antibody fragments like single-chain variable fragments (scFvs) are starting to see their way into the clinic in BiTEs and CAR T. Sc…
- College: College of Arts & Sciences
- Inventors: Magliery, Thomas; Do, Jamie; Han, Jeong Min "Mina"; Zhu, Ian
- Licensing Officer: Panic, Ana
Humanized SSTR2 mAb and ADC to target SSTR2+ tumors
TS-066912 — Targeted humanized mAbs and ADCs for cancer treatment
The Liu Lab
Dr. Xiaoguang “Margaret” Liu applies her industry experience (Lonza, Merck, and Life Technologies) in cell line and process development towards her lab’s focus on targeted anti-cancer therapies including monoclonal antibodies, antibody-drug conjugates, and gene therapi…
- College: College of Engineering (COE)
- Inventors: Liu, Xiaoguang "Margaret"; Zhou, Lufang
- Licensing Officer: Schworer, Adam
Novel Antibodies Targeting IL-2
TS-066051 — Novel antibodies targeting IL-2 with the ability to inhibit IL-2 signaling through IL-2 Rαβg to a greater extent than through IL-2 Rβg.
IL-2 and its receptor IL-2R are known to play multiple roles in shaping the immune response, including both immune activation and tolerance. Expression of intermediate-affinity IL-2 receptors by different immune cell subsets determines cellular sensitivity to IL-2. However, the dynamic interplay bet…
- College: OSU Wexner Medical Center
- Inventors: Rubinstein, Mark
- Licensing Officer: Willson, Christopher
Nanobody-based Protein Degraders for the Treatment of Neurodegenerative Diseases
TS-062678 — Neurodegenerative diseases including Alzheimer's and Parkinson’s diseases, amyotrophic lateral sclerosis (ALS), prion diseases, and among others affect millions of people in the US. These diseases are relentless, often fatal, and affect fundamental functions – things like moving, bre…
- College: College of Medicine (COM)
- Inventors: Chu, Nam; Le, Nhat
- Licensing Officer: Willson, Christopher
Addressing the Challenges in Cancer Imaging
TS-062545 — The Need: Addressing the Challenges in Cancer Imaging
Cancer continues to be a major cause of global mortality, with over 10% of all deaths attributed to this devastating disease. Despite significant advancements in cancer research, there remains a critical need to enhance current techniques for pr…
- College: College of Arts & Sciences
- Inventors: Magliery, Thomas; Long, Nicholas; Sullivan, Brandon
- Licensing Officer: Panic, Ana
Addressing the Challenges in Cancer Imaging
TS-062544 — The Need: Addressing the Challenges in Cancer Imaging
Cancer continues to be a major cause of global mortality, with over 10% of all deaths attributed to this devastating disease. Despite significant advancements in cancer research, there remains a critical need to enhance current techniques for pr…
- College: College of Arts & Sciences
- Inventors: Magliery, Thomas; Allen, Heather; Alten, Edward; Hitchcock, Charles; Long, Nicholas; Martin, Edward; Sullivan, Brandon
- Licensing Officer: Panic, Ana
Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 —
A novel monoclonal antibody (PIIO-1) targeting the ligand-free form of GARP, the non-signaling docking receptor for TGFβ. PIIO-1 distrupts transforming growth factor-β (TGF-β) signalling in the tumor microenvironment, primarily on T regulatory cells, consequently augmenting anti-tumor immunity and overcoming ICB resistance . Unlike market competitors, ABBV-151 and DS-1055a which bind the TGF-β1/GARP complex, PIIO-1 prevents activation of all 3 TGF-β isoforms, avoiding isoform compensation and avoiding the potential on-target, adverse effects of binding the TGF-β1/GARP complex found on platelets.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the activation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by induci…
- College: College of Medicine (COM)
- Inventors: Li, Zihai
- Licensing Officer: He, Panqing
Potential uses of IgG Fc for treating human diseases
TS-036778 —
Infectious diseases present a problem for treatment, with concerns for the overuse of antibiotic medicine, inefficiency of modern medicines, and a need in the market for novel technologies that will target and work in conjunction with the host immune system, rather than depending on external mecha…
- College: College of Medicine (COM)
- Inventors: Dai, Hongsheng; Caligiuri, Michael; Yu, Jianhua
- Licensing Officer: Taysavang, Panya
Anti-NCL Immunoagent for Cancer Diagnosis and Therapy
TS-015251 — Nucleolin (NCL) is up-regulated in cancer cells, and modulates pro-tumorigenic pathways and chemoresistance. This anti-NCL agent binds and blocks NCL signaling, and may be optimized as cancer therapeutic and diagnostic tool.
Despite huge advancements in detection and treatment, cancer remains a top world health concern. One of the major limitations of current technology is adequately detecting tumor margins and micrometastases. Even with aggressive tumor resection and adjuvant chemotherapy or radiotherapy, tumor cells…
- College: College of Medicine (COM)
- Inventors: Palmieri, Dario; Croce, Carlo
- Licensing Officer: Taysavang, Panya
